Stronger. Together.

Collaboration is a cornerstone of Apogee’s growth strategy. Apogee is actively seeking partnerships with biotechnology companies, academic institutions, and other organizations that share Apogee’s passion for innovation in immune-driven disease areas and ECS. Apogee believes that combining strengths with strategic partners can accelerate the development of breakthrough therapies and amplify Apogee’s impact.

Apogee invites potential partners to explore a range of collaboration opportunities with it, including:

  • In-Licensing & Asset Acquisition: Apogee is interested in in-licensing promising drug candidates, patented technologies, or novel intellectual property in its core focus areas. If a biotech or research group has a compelling therapeutic asset targeting autoimmune or inflammatory diseases, respiratory illnesses, endometriosis, or the ECS, Apogee can provide the development expertise and resources to advance these. Apogee is also open to acquiring early-stage companies or assets that complement Apogee’s pipeline and align with its strategic vision.

  • Joint Ventures & Co-Development: Apogee is open to co-development agreements, joint ventures, and research collaborations where both parties bring unique capabilities to the table. For example, Apogee can partner with academic laboratories on translational research or co-create new companies around synergistic drug programs. By leveraging each partner’s strengths, Apogee aims to drive programs forward more efficiently and share in the success. Apogee thrives on collaborative science and welcome opportunities to jointly develop novel therapies with like-minded biotech innovators.

  • Strategic Investment & Partnerships: Backed by an investment firm, Apogee is well-positioned to form strategic financial partnerships. Apogee can structure deals that include equity investment, option agreements, or mergers and acquisitions for especially high-potential opportunities. In cases where a transformative medicine or platform aligns closely with its mission, Apogee (together with its parent company) may invest capital or consider an acquisition to integrate that asset into its portfolio. Apogee’s flexible funding and deal structures enable creative partnering solutions that create win-win outcomes.

Beyond these scientific criteria, Apogee also considers strategic factors to maximize the impact of its work. Apogee evaluates the intellectual property landscape and competitive environment for each potential program, favoring opportunities where it can secure strong IP positions and where there is relatively limited direct competition. By aligning robust science with strategic positioning, Apogee ensures that its efforts are not only scientifically sound but also poised to deliver unique medicines that stand out in the biotechnology space.